-
Article
Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study
This pilot study evaluated the imaging performance of pretargeted immunological positron emission tomography (immuno-PET) using an anti-carcinoembryonic antigen (CEA) recombinant bispecific monoclonal antibody...
-
Article
CD84 is a survival receptor for CLL cells
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5+ B lymphocytes in peripheral blood, lymphoid organs and bone marrow. The main feature of the disease is accumulation of the malign...
-
Article
Open AccessDevelopment of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
Radiolabelled antibody targeting of cancer is limited by slow blood clearance. Pretargeting with a non-radiolabelled bispecific monoclonal antibody (bsMAb) followed by a rapidly clearing radiolabelled hapten p...
-
Article
The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD
In contrast to the conventional immunosuppressive agents and nonselective T-cell-depleting antibodies, selective depletion of donor alloreactive T cells and/or host APCs, particularly DCs, represents a novel a...
-
Article
Open AccessPlacental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement
During metastasis, cancer cells migrate away from the primary tumour and invade the circulatory system and distal tissues. The stimulatory effect of growth factors has been implicated in the migration process....
-
Article
Open AccessIn vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
-
Article
Novel radiolabeled antibody conjugates
This article reviews the development of radioimmunoconjugates as a new class of cancer therapeutics. Numerous conjugates involving different antigen targets, antibody forms, radionuclides and methods of radioc...
-
Article
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies
The vast majority of non-Hodgkin's lymphomas are of B-cell phenotype. Development of unlabeled or radiolabeled therapeutic monoclonal antibodies against the cell surface antigen, CD20, has revolutionized the t...
-
Article
Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody
A comparison of the therapeutic efficacy of a new bispecific monoclonal antibody (bsMAb)-pretargeting system vs the conventional direct targeting modality was undertaken. A bsMAb was made by coupling the Fab′ of ...
-
Article
Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22
LL2 is an anti-CD22 pan-B-cell monoclonal antibody which, when radiolabeled, has a high sensitivity for detecting B-cell, non-Hodgkin’s lymphoma (NHL), as well as an antitumor efficacy in therapeutic applicat...
-
Chapter
Radioimmunotherapy of CEA-Expressing Cancers: Clinical Results with an 131I-Labeled Anti-CEA monoclonal IgG1
Fifty-seven patients with CEA-expressing tumors in very advanced stages were treated with 44–268 mCi of the 131 I-labeled murine anti-CEA monoclonal antibody NP-4. Differences in pharmacokinetics were found betwe...
-
Chapter
Pharmacokinetic Evaluation of Two Monoclonal Antibodies as Possible Immunoscintigraphy Agents for Pancreatic Cancer in Humans
In this study we evaluated the biodistribution and potential usefulness for tumor immunoscintigraphy of two recently developed monoclonal antibodies (MoAbs), termed AR-3 and PAM4, in patients with pancreatic c...
-
Chapter
Prospects for Cancer Imaging and Therapy with Radioimmunoconjugates
Immunological methods for cancer therapy have been sought for over a century (DeLand and Goldenberg 1986), especially in an attempt to achieve a more targeted, tumor-selective approach. This immunotherapy has inv...
-
Chapter
Advances in Cancer Imaging and Therapy with Radiolabelled Antibodies
Monoclonal antibody (MAb) technology has generated considerable interest in the development of approaches to improve the management of cancer patients, as well as our understanding of some aspects of the malig...
-
Chapter and Conference Paper
Immunological Approaches for Early Cancer Detection
Much discussion at this meeting has been devoted to the terms and definitions of “incipient” and “minimal” cancer. Since there is confusion in the literature on these issues, it is not surprising that we are a...
-
Chapter
In Vivo Radioimmunodetection of Cancer
The application of antibodies in the therapy or diagnosis of malignancies began at the turn of the century. In 1895, Héricourt and Richet (1895a) developed antisera from a human oesteogenic sarcoma in donkey a...
-
Article
CEA (carcinoembryonic antigen): Its role as a marker in the management of cancer
A Consensus Development Conference was held at the National Institutes of Health from September 29-October 1, 1980, to address issues concerning the role of carcinoembryonic antigen (CEA) as a marker in the ma...
-
Article
Comparison of the sensitivity of the indirect, antibody-conjugated and the triple-bridge immunoperoxidase methods for immunohistochemical detection of carcinoembryonic antigen
A comparison between two immunoperoxidase staining procedures, a triple-bridge and an indirect, antibody-conjugated method, was made to determine the relative sensitivity of each technique in the detection of ...
-
Article
Immunoperoxidase staining of carcinoembryonic antigen in urinary bladder cancer
An immunoperoxidase study of the presence of carcinoembryonic antigen (CEA) in primary cancers of the urinary bladder, metastases to the bladder, non-malignant diseased bladder, and normal bladder tissues reve...
-
Article
Localization by immunoperoxidase and estimation by radioimmunoassay of carcinoembryonic antigen in colonic polyps
A 3-layer immunoperoxidase technique was used to demonstrate carcinoembryonic antigen (CEA) in colonic polyps from patients with or without previous or concurrent malignancy. CEA was demonstrated in a higher p...
